5月11日 - ** 药物开发商Erasca（ERAS.O）的股价在盘前交易中上涨8%，至10.92美元
(link) ** Erasca表示已与默克公司（MRK.N）签署了一项临床试验合作及供货协议，旨在测试其实验性抗癌药ERAS-0015与默克公司的Keytruda联合使用
** 该试验将针对因RAS基因突变导致实体瘤的患者，研究该联合疗法
** Erasca将负责开展该研究，而默克将免费提供Keytruda
** 上月，Erasca曾表示一名患者在ERAS-0015的早期临床试验中死亡 (link)
** 在同一项试验中，对于此前经治疗未见疗效的肺癌患者，ERAS-0015使62%的患者肿瘤缩小
** 截至上一交易日收盘，ERAS今年以来累计上涨172%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.